Axovant Sciences (AXON) Releases Earnings Results, Hits Estimates

Axovant Sciences (NASDAQ:AXON) posted its earnings results on Thursday. The biotechnology company reported ($0.27) EPS for the quarter, meeting analysts’ consensus estimates of ($0.27), Zacks reports.

AXON traded up $0.03 during trading on Friday, reaching $1.25. The company had a trading volume of 1,241,576 shares, compared to its average volume of 1,447,258. The company has a market cap of $149.18 million, a PE ratio of -0.61 and a beta of 1.21. Axovant Sciences has a 52 week low of $0.93 and a 52 week high of $6.59. The company has a quick ratio of 1.97, a current ratio of 1.97 and a debt-to-equity ratio of 1.68.

A number of research analysts have recently commented on the company. BidaskClub upgraded Axovant Sciences from a “strong sell” rating to a “sell” rating in a research report on Tuesday, October 16th. ValuEngine upgraded Axovant Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Oppenheimer reiterated a “hold” rating on shares of Axovant Sciences in a research report on Sunday, November 11th. Zacks Investment Research downgraded Axovant Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, November 13th. Finally, Jefferies Financial Group upgraded Axovant Sciences from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research report on Monday, December 17th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $3.81.

In related news, major shareholder Svf Investments (Uk) Ltd purchased 10,000,000 shares of the stock in a transaction that occurred on Tuesday, December 18th. The stock was bought at an average cost of $1.00 per share, for a total transaction of $10,000,000.00. Following the completion of the transaction, the insider now directly owns 99,285,714 shares in the company, valued at $99,285,714. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 6.00% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “Axovant Sciences (AXON) Releases Earnings Results, Hits Estimates” was first published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at

About Axovant Sciences

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.

Read More: Average Daily Trade Volume – ADTV

Earnings History for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with's FREE daily email newsletter.

Leave a Reply